Back to News
Dec 18, 2025 4:00 AM

FoRx Therapeutics Announces USD 50M Series A Financing, Enabling Clinical Data Readout for Potential Best-in-Class PARG Inhibitor

Funding to support Phase 1 clinical development of best-in-class PARG inhibitor candidate FORX-428

FORX-428 is potential new treatment option for patients whose cancers are resistant to, or have become resistant to, PARP inhibitors

Initial data expected in mid-2026 from open-label Phase 1 study in advanced solid tumors

Basel, Switzerland, December 18, 2025, FoRx Therapeutics, a clinical-stage biotechnology company developing precision anti-cancer therapeutics, today announced the close of an insider-led USD 50 million (CHF 40 million) Series A financing. The funding will be used to advance Phase 1 clinical development of its lead drug candidate, FORX-428, a potential best-in-class PARG (poly (ADP-ribose) glycohydrolase) inhibitor designed to target and disrupt the DNA Damage Response (DDR) in advanced solid tumors.

Existing investors including EQT Life Sciences, Pfizer Ventures, Novartis Venture Fund and M Ventures participated in the financing including a first closing in June 2024, which provided funding through the Investigational New Drug (IND) application for FORX-428 and the initiation of the Phase 1 trial.

Tarig Bashir, CEO of FoRx Therapeutics, said: "The FoRx team is proud to have earned the continued trust and conviction of this sophisticated ...